What remains unknown about epitalon

Human effects have not been adequately checked

FDA means the US medicines agency.

FDA’s July 2026 epitalon review found no studies that checked its safety in people.

A lack of reports does not establish safety, as FDA noted in that review.

Epitalon had no official US prescribing document as of September 28, 2026.

The missing information includes what happens with other medicines and which people need to avoid it.

• Ask which human data the proposed plan relies on.
• Tell the clinician about current medicines and any pregnancy or breastfeeding plans.
• Ask what cannot be answered from the available research.

A cancer concern is not a proven human outcome

FDA raised a possible cancer risk because epitalon may lengthen telomeres, the caps on the ends of the threads that carry a cell’s instructions.

Longer telomeres are generally linked to a greater cancer risk, according to FDA’s July 2026 review.

That concern is based on how it might work, not on an observed human cancer case.

• Ask how that uncertainty changes the decision.
• Do not turn an animal finding about fewer tumours into a promise about people.

Quality is another unanswered part

FDA also raised concerns about epitalon impurities and clumps that may trigger the body’s immune defences after injection.

• Ask for the identity of whoever prepares the product.
• Ask what evidence answers the quality concern for that exact preparation.
• Keep unresolved answers in view alongside any proposed benefit.